STATINS AND ACE INHIBITORS FOR TEENS WITH TYPE 1

The adolescent Type 1 diabetes cardio-renal intervention trial (AdDIT)

Background to research
Many adolescents with Type 1 diabetes find it difficult to maintain good control of their blood glucose. This can lead to early evidence of diabetes-related complications such as increased protein in the urine, which suggests that damage is being done to the kidneys. ACE inhibitors and statins are drugs used in adults to help protect the heart and kidneys by lowering blood pressure and lipid levels. However, they have not yet been evaluated for use in adolescents.

Project aims
This study, which is being co-funded by Diabetes UK, JDRF and the British Heart Foundation, will use a randomised controlled trial to determine whether ACE inhibitors and statins are safe, effective and well tolerated in adolescents with Type 1 diabetes. The study will involve screening 4,500 adolescents aged 11-15 in the UK, Australia and Canada in order to recruit 500 participants at ‘high risk’ of complications and 400 in the study of low-risk young people. Participants will then be randomised to receive either an ACE inhibitor, a statin, a combination of both or a placebo (dummy medication with no active ingredient) and their progress studied over a three to four year follow-up period.


Benefit or potential value for people with diabetes
The AdDIT study will provide important data on the potential protective effects of ACE Inhibitors and/or Statins in high-risk adolescents with Type 1 diabetes. Ultimately this will have an important impact on future recommendations relating to the management of Type 1 diabetes during adolescence and the effect of early intervention at this early stage. Specifically the study will determine whether use of these types of drugs should be implemented in addition to encouraging young people to achieve good glycaemic control.

https://www.diabetes.org.uk/

graham64 wrote:

The adolescent Type 1 diabetes cardio-renal intervention trial (AdDIT)

Background to research
Many adolescents with Type 1 diabetes find it difficult to maintain good control of their blood glucose. This can lead to early evidence of diabetes-related complications such as increased protein in the urine, which suggests that damage is being done to the kidneys. ACE inhibitors and statins are drugs used in adults to help protect the heart and kidneys by lowering blood pressure and lipid levels. However, they have not yet been evaluated for use in adolescents.

Project aims
This study, which is being co-funded by Diabetes UK, JDRF and the British Heart Foundation, will use a randomised controlled trial to determine whether ACE inhibitors and statins are safe, effective and well tolerated in adolescents with Type 1 diabetes. The study will involve screening 4,500 adolescents aged 11-15 in the UK, Australia and Canada in order to recruit 500 participants at ‘high risk’ of complications and 400 in the study of low-risk young people. Participants will then be randomised to receive either an ACE inhibitor, a statin, a combination of both or a placebo (dummy medication with no active ingredient) and their progress studied over a three to four year follow-up period.


Benefit or potential value for people with diabetes
The AdDIT study will provide important data on the potential protective effects of ACE Inhibitors and/or Statins in high-risk adolescents with Type 1 diabetes. Ultimately this will have an important impact on future recommendations relating to the management of Type 1 diabetes during adolescence and the effect of early intervention at this early stage. Specifically the study will determine whether use of these types of drugs should be implemented in addition to encouraging young people to achieve good glycaemic control.

https://www.diabetes.org.uk/

Brilliant if T1 teens haven't enough to cope with add more drugs with dubious benefits into the equation 

Still DUK sponsors will approve of the £89,999 grant for this project